A Multiple Modality Approach Combining the Effect of Conditioning with Adoptive Chemoimmunotherapy

References

• Berd D. Immunotherapy of melanoma with autologous tumor vaccine preceded by low dose cyclophosphamide. Human Tumor Antigens and Specific Tumor Therapy. Alan R. Liss, Inc., New York 1989; 297–306
   Google Scholar
• Berd D., Maquire H. C., Jr., Mastrangelo M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Research 1986; 46: 2572–2577
   PubMed Web of Science ®Google Scholar
• Besedovsky H., Del Rey A., Normann S. Host endocrine responses during tumor growth. Immunity to Cancer II. Alan R. Liss, Inc., New York 1989; 203–213
   Google Scholar
• Bystryn J.-C., Dugan M., Oratz K., Spryer J., Harris M. N., Roses D. F. Vaccine immunotherapy of human malignant melanoma: Relationship between method of immunization, immunogenicity, and tumor progression. Human Tumor Antigens and Specific Tumor Therapy. Alan R. Liss. Inc., New York 1989; 307–315
   Google Scholar
• Cheever M. A., Greenberg P. D., Fefer A. Potential for specific cancer therapy with immune T-lymphocytes. Journal of Biological Response Modifiers 1984; 3: 113–127
   PubMedGoogle Scholar
• Cunningham T. J., Olson K. B., Laffin R., Horton J., Sullivan J. Treatment of advanced cancer with active immunization. Cancer 1969; 24: 932–937
   PubMed Web of Science ®Google Scholar
• Dye E. S., North R. J. T-cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastasis. Journal of Experimental Medicine 1981; 154: 1033–1042
   PubMed Web of Science ®Google Scholar
• Fareed G. C., Mendiaz E., Sen A., Juillard G. J. F., Weisenburger T. H., Totanes T. Novel antigenic markers of human tumor regression. Journal of Biological Response Modifiers 1988; 7: 11–23
   PubMedGoogle Scholar
• Ghanta V. K., Hiramoto N. S., Solvason H. B., Soong S.-J., Hiramoto R. S. Conditioning: A New Approach to Immunotherapy. Cancer Research 1990; 50: 1295–4299
   Web of Science ®Google Scholar
• Ghanta V. K., Hiramoto R. N., Solvason H. B., Spector N. H. Influence of conditioned natural immunity on tumor growth. Annals of the New York Academy Science 1987; 496: 637–646
   PubMed Web of Science ®Google Scholar
• Gorczynski R. M., Kennedy M., Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. Journal of Immunology 1985; 134: 4261–4266
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Cheever M. A. Treatment of disseminated leukemia with cyclophosphamide and immune cells: Tumor immunity reflects long-term persistence of tumor-specific donor T. cells. Journal of Immunology 1984; 133: 3401–3407
   PubMed Web of Science ®Google Scholar
• Greenberg P. D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2′-cells: Cytolytic T-cells can mediate eradication of disseminated leukemia. Journal of Immunology 1986; 136: 1917–1922
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1′2-lymphocytes. Journal of Experimental Medicine 1981; 154: 952–963
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1′2-T-cells. Tumor eradication dries not require participation of cytotoxic T-cells. Journal of Experimental Medicine 1985; 136: 1122–1135
   Google Scholar
• Hiramoto K. N., Solvason H., Ghanta V., Lorden J., Hiramoto N. Effect of reserpine on retention of the conditioned NK cell response. Pharmacology, Biochemistry and Behavior 1990; 36: 51–56
   PubMed Web of Science ®Google Scholar
• Hoon D. S. B., Foshag L. J., Nizze A. S., Bohman K., Morton D. L. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Research 1990; 50: 5358–5364
   PubMed Web of Science ®Google Scholar
• Key M. E., Hoover H. C., Jr., Hanna M. G., Jr. Active specific immunotherapy as all adjuvant to the treatment of metastatic solid tumors: Present and future prospects. Advances Immunology and Cancer Therapy 1985; 1: 195–219
   PubMedGoogle Scholar
• Levy S. M., Herberman K. B., Maluish A. E., Schlien B., Lippinan M. NK activity and host behavior: Biological vulnerability associated with cancer patient coping style. Proceedings of the 1st International Workshop on Neuroimmunomodulation 1985; 205–209
   Google Scholar
• Marsh B., Flynn I., Enneking W. Immunologic aspects of osteosarcoma and their application to therapy. Journal of Bone and Joint Surgery 1972; 54: 1367–1397
   Google Scholar
• McCune C. S., Schapira D. V., Henshaw E. C. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastasis. Cancer 1981; 47: 1984–1987
   PubMed Web of Science ®Google Scholar
• North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. Journal of Experimental Medicine 1982; 155: 1063–1074
   PubMed Web of Science ®Google Scholar
• Parmiani G., Sensi M. L., Carbone G., Colombo M., Pierotti M., Ballinari D., Hilgers J., Hilkens J. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and nnn-H-2 alloimnune BALB/c mice. International Journal of Cancer 1982; 29: 323–332
   PubMed Web of Science ®Google Scholar
• Sensi M. L., Orosz C. G., Bach F. H. Alloantigen-induced cytotoxicity against syngeneic tumor cells. Analysis at the clonal level. Journal of Immunology 1984; 132: 3218–3225
   PubMed Web of Science ®Google Scholar
• Sensi M. L., Parenza M., Parmiani G. Alloreactivity and tumor antigens: Generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. Journal of the National Cancer Institute 1983; 70: 291–297
   PubMedGoogle Scholar
• Solvason H. B., Ghanta V. K., Hiramoto K. N. Conditioned augmentation of natural killer cell activity. Independence from nociceptive effects and dependence on interferon-β. Journal of Immunology 1988; 140: 661–665
   PubMed Web of Science ®Google Scholar
• Solvason H. B., Hiramoto R. N., Ghanta V. K. Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice. Brain, Behavior and Immunity 1989; 3: 247–262
   PubMedGoogle Scholar
• Solvason H. R., Ghanta V. K., Soong S-J., Hiramoto R. N. Interferon interaction with the CNS is required for the conditioning of the NK cell response. Progress in NeuroEndocrinImmunology 1991; 4: 258–264
   Google Scholar
• Spiegel D., Kraemer H. C., Bloom J. K., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. The Lancet 1989; 2: 888–891
   PubMed Web of Science ®Google Scholar
• Tai T., Cahan L. D., Tsuchida T., Saxton R. E., Irie R., Morton D. L. Immunogenicity of melanoma-associated gangliosides in cancer patients. International Journal of Cancer 1985; 35: 607–612
   PubMed Web of Science ®Google Scholar
• Vinnitsky V. B. Neurohumoral mechanisms of the formation of antitumoral activity. Annals of the New York Academy of Sciences 1988; 521: 195–214
   PubMed Web of Science ®Google Scholar